Percutaneous coronary intervention in patients with diabetes: Current concepts and future directions

Ehrin J. Armstrong, Johannes Waltenberger, Jason H Rogers

Research output: Contribution to journalArticle

11 Citations (Scopus)

Abstract

Patients with diabetes and coronary artery disease represent a challenging and growing subset of the population. Although surgical revascularization is the preferred treatment for patients with diabetes and multivessel coronary artery disease with stable angina, a significant proportion of diabetic patients undergo percutaneous revascularization due to comorbidities, presence of single-vessel disease, or presentation with myocardial infarction. The development of drug-eluting stents has significantly improved the results of percutaneous revascularization among diabetic patients, but a number of challenges remain, including higher rates of restenosis and stent thrombosis among diabetic patients. With current technologies, the outcomes of diabetic patients treated with noninsulin agents have approached that of nondiabetic patients. In comparison, patients with diabetes who require insulin therapy represent a high-risk cohort with increased rates of target vessel failure after coronary revascularization. The development of bioresorbable stents and new drug elution systems may provide additional future benefit among patients with diabetes undergoing percutaneous coronary artery revascularization.

Original languageEnglish (US)
Pages (from-to)581-589
Number of pages9
JournalJournal of diabetes science and technology
Volume8
Issue number3
DOIs
StatePublished - 2014

Fingerprint

Percutaneous Coronary Intervention
Medical problems
Stents
Insulin
Pharmaceutical Preparations
Coronary Artery Disease
Direction compound
Drug-Eluting Stents
Stable Angina
Comorbidity
Coronary Vessels
Thrombosis
Myocardial Infarction
Technology
Therapeutics

Keywords

  • Coronary artery disease
  • Diabetes
  • Drug-eluting stents

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Internal Medicine
  • Bioengineering
  • Biomedical Engineering

Cite this

Percutaneous coronary intervention in patients with diabetes : Current concepts and future directions. / Armstrong, Ehrin J.; Waltenberger, Johannes; Rogers, Jason H.

In: Journal of diabetes science and technology, Vol. 8, No. 3, 2014, p. 581-589.

Research output: Contribution to journalArticle

@article{4c57124ec63b4b54bc392fb4d74ffe57,
title = "Percutaneous coronary intervention in patients with diabetes: Current concepts and future directions",
abstract = "Patients with diabetes and coronary artery disease represent a challenging and growing subset of the population. Although surgical revascularization is the preferred treatment for patients with diabetes and multivessel coronary artery disease with stable angina, a significant proportion of diabetic patients undergo percutaneous revascularization due to comorbidities, presence of single-vessel disease, or presentation with myocardial infarction. The development of drug-eluting stents has significantly improved the results of percutaneous revascularization among diabetic patients, but a number of challenges remain, including higher rates of restenosis and stent thrombosis among diabetic patients. With current technologies, the outcomes of diabetic patients treated with noninsulin agents have approached that of nondiabetic patients. In comparison, patients with diabetes who require insulin therapy represent a high-risk cohort with increased rates of target vessel failure after coronary revascularization. The development of bioresorbable stents and new drug elution systems may provide additional future benefit among patients with diabetes undergoing percutaneous coronary artery revascularization.",
keywords = "Coronary artery disease, Diabetes, Drug-eluting stents",
author = "Armstrong, {Ehrin J.} and Johannes Waltenberger and Rogers, {Jason H}",
year = "2014",
doi = "10.1177/1932296813517058",
language = "English (US)",
volume = "8",
pages = "581--589",
journal = "Journal of diabetes science and technology",
issn = "1932-2968",
publisher = "Diabetes Technology Society",
number = "3",

}

TY - JOUR

T1 - Percutaneous coronary intervention in patients with diabetes

T2 - Current concepts and future directions

AU - Armstrong, Ehrin J.

AU - Waltenberger, Johannes

AU - Rogers, Jason H

PY - 2014

Y1 - 2014

N2 - Patients with diabetes and coronary artery disease represent a challenging and growing subset of the population. Although surgical revascularization is the preferred treatment for patients with diabetes and multivessel coronary artery disease with stable angina, a significant proportion of diabetic patients undergo percutaneous revascularization due to comorbidities, presence of single-vessel disease, or presentation with myocardial infarction. The development of drug-eluting stents has significantly improved the results of percutaneous revascularization among diabetic patients, but a number of challenges remain, including higher rates of restenosis and stent thrombosis among diabetic patients. With current technologies, the outcomes of diabetic patients treated with noninsulin agents have approached that of nondiabetic patients. In comparison, patients with diabetes who require insulin therapy represent a high-risk cohort with increased rates of target vessel failure after coronary revascularization. The development of bioresorbable stents and new drug elution systems may provide additional future benefit among patients with diabetes undergoing percutaneous coronary artery revascularization.

AB - Patients with diabetes and coronary artery disease represent a challenging and growing subset of the population. Although surgical revascularization is the preferred treatment for patients with diabetes and multivessel coronary artery disease with stable angina, a significant proportion of diabetic patients undergo percutaneous revascularization due to comorbidities, presence of single-vessel disease, or presentation with myocardial infarction. The development of drug-eluting stents has significantly improved the results of percutaneous revascularization among diabetic patients, but a number of challenges remain, including higher rates of restenosis and stent thrombosis among diabetic patients. With current technologies, the outcomes of diabetic patients treated with noninsulin agents have approached that of nondiabetic patients. In comparison, patients with diabetes who require insulin therapy represent a high-risk cohort with increased rates of target vessel failure after coronary revascularization. The development of bioresorbable stents and new drug elution systems may provide additional future benefit among patients with diabetes undergoing percutaneous coronary artery revascularization.

KW - Coronary artery disease

KW - Diabetes

KW - Drug-eluting stents

UR - http://www.scopus.com/inward/record.url?scp=84900812108&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900812108&partnerID=8YFLogxK

U2 - 10.1177/1932296813517058

DO - 10.1177/1932296813517058

M3 - Article

C2 - 24876623

AN - SCOPUS:84900812108

VL - 8

SP - 581

EP - 589

JO - Journal of diabetes science and technology

JF - Journal of diabetes science and technology

SN - 1932-2968

IS - 3

ER -